Department of Health Systems and Population Health, University of Washington, 3980 15th Ave NE, Seattle, WA, USA.
Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, 1959 Pacific Street NE, Seattle, WA, USA.
Int J Drug Policy. 2022 Nov;109:103825. doi: 10.1016/j.drugpo.2022.103825. Epub 2022 Aug 10.
Syringe services programs (SSPs) provide critical evidence-based public health services that decrease harms from drug use for people who use drugs (PWUD). Many SSPs have experienced significant and evolving COVID-19-related disruptions. We aimed to characterize the impacts of COVID-19 on SSP operations in the United States approximately one year into the pandemic.
Participating sites, selected from a national sample of SSPs, completed a semi-structured interview via teleconference and brief survey evaluating the impacts of COVID-19 on program operations. Data collection explored aspects of program financing, service delivery approaches, linkages to care, and perspectives on engaging PWUD in services one year into the pandemic. Interview data were analyzed qualitatively using Rapid Assessment Process. Survey data were analyzed using descriptive statistics and triangulated with qualitative findings.
27 SSPs completed study-related interviews and surveys between February 2021 - April 2021. One year into the pandemic, SSPs reported continuing to adapt approaches to syringe distribution in response to COVID-19, and identified multiple barriers that hindered their ability to engage program participants in services, including 1) isolation and decreased connectivity with participants, 2) resource restrictions that limit responsiveness to participant needs, 3) reduced capacity to provide on-site HIV/HCV testing and treatment linkages, and 4) changing OUD treatment modalities that were a "double-edged sword" for PWUD. Quantitative survey responses aligned with qualitative findings, highlighting increases in the number of syringes distributed, increases in mobile and home delivery services, and reductions in on-site HIV and HCV testing.
These data illuminate persistent and cascading risks of isolation, reduced access to services, and limited engagement with program participants that resulted from COVID-19 and continue to create barriers to the delivery of critical harm reduction services. Findings emphasize the need to ensure SSPs have the resources and capacity to adapt to changing public health needs, particularly as the COVID-19 pandemic continues to evolve.
注射服务项目 (SSP) 为吸毒者 (PWUD) 提供了关键的循证公共卫生服务,可减少吸毒造成的危害。许多 SSP 都经历了与 COVID-19 相关的重大且不断演变的中断。我们旨在描述 COVID-19 对美国 SSP 运营的影响,这是大流行一年后的情况。
从全国 SSP 样本中选择参与的站点,通过电话会议完成半结构化访谈和简短调查,评估 COVID-19 对项目运营的影响。数据收集探讨了项目融资、服务提供方法、与护理的联系以及在大流行一年后参与 PWUD 服务的观点等方面。使用快速评估过程对访谈数据进行定性分析。使用描述性统计数据和与定性结果的三角剖分分析调查数据。
27 个 SSP 于 2021 年 2 月至 4 月期间完成了与研究相关的访谈和调查。在大流行一年后,SSP 报告继续调整针具分发方法以应对 COVID-19,并确定了多个阻碍他们为参与者提供服务的能力的障碍,包括 1)隔离和与参与者的联系减少,2)限制资源限制了对参与者需求的响应能力,3)减少现场 HIV/HCV 检测和治疗联系的能力,以及 4)改变 OUD 治疗模式,这对 PWUD 来说是一把“双刃剑”。定量调查结果与定性结果一致,突出了分发的注射器数量增加、移动和上门服务增加以及现场 HIV 和 HCV 检测减少。
这些数据揭示了由于 COVID-19 导致的持续存在的隔离、服务获取减少和与参与者有限接触的风险,这继续为提供关键的减少伤害服务造成障碍。研究结果强调需要确保 SSP 具备适应不断变化的公共卫生需求的资源和能力,特别是随着 COVID-19 大流行的持续演变。